Concepedia

Scott R. Daigle

SR

33

Publications

4.3K

Citations

23

H-Index

2010

Active since

Affiliations

Epizyme (United States)(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Scott R. Daigle is an author at Epizyme (United States) specializing in medicine, tumor biology, and cell biology.

Top concepts

Publications per year

2010–2024

33

Publications

33

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen et al. · Cancer Cell · 2011 · 923 citations · Full text

, , +8

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen et al. · Blood · 2013 · 718 citations · Full text

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Pau Montesinos, Christian Récher, Susana Vives et al. · New England Journal of Medicine · 2022 · 448 citations · Full text

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2018 · 442 citations · Full text

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l

Aniruddha J. Deshpande, Liying Chen, Maurizio Fazio et al. · Blood · 2013 · 172 citations · Full text

Rows per page

1–5 of 33